Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody

(2015) Li Peng et al.   mAbs

A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product like Format

(2015) Xiaodong Xiao et al.   PLoS One

A Conformational Investigation of Propeptide Binding to the Integral Membrane Protein γ-Glutamyl Carboxylase Using Nanodisc Hydrogen Exchange Mass Spectrometry

(2014) Christine H. Parker et al.   BIOCHEMISTRY

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer

(2014) Bertrand Allard et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Mechanisms of Neutralization of a Human Anti-α-toxin Antibody

(2014) Vaheh Oganesyan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications

(2013) Hui Wei et al.   DRUG DISCOVERY TODAY

Identification of sulfonic acids as efficient ecto-5′-nucleotidase inhibitors

(2013) Jamshed Iqbal et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells

(2013) M. G. Terp et al.   JOURNAL OF IMMUNOLOGY

Use of Allosteric Targets in the Discovery of Safer Drugs

(2013) Ashok Kumar Grover   MEDICAL PRINCIPLES AND PRACTICE

Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas

(2013) Shuo Xu et al.   NEURO-ONCOLOGY

CD73-Deficient Mice Are Resistant to Carcinogenesis

(2012) J. Stagg et al.   CANCER RESEARCH

New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors

(2012) Vandana Lamba et al.   CURRENT PHARMACEUTICAL DESIGN

Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?

(2012) V. Kumar   Purinergic Signalling

Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling

(2012) Karen Knapp et al.   STRUCTURE

CD73: a potent suppressor of antitumor immune responses

(2012) Paul. A. Beavis et al.   TRENDS IN IMMUNOLOGY

On the Solution Conformation and Dynamics of the HIV-1 Viral Infectivity Factor

(2011) Sean R. Marcsisin et al.   JOURNAL OF MOLECULAR BIOLOGY

RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells

(2010) Xiuling Zhi et al.   CANCER SCIENCE

The Utility of Hydrogen/Deuterium Exchange Mass Spectrometry in Biopharmaceutical Comparability Studies

(2010) Damian Houde et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural characterization of a human Fc fragment engineered for lack of effector functions

(2008) Vaheh Oganesyan et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Adenosine receptors in regulation of dendritic cell differentiation and function

(2008) S. V. Novitskiy et al.   BLOOD

The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation

(2008) Luci Bavaresco et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases)

(2008) Younis Baqi et al.   Purinergic Signalling